Molecule Details
| InChIKey | DRLCSJFKKILATL-YWCVFVGNSA-N |
|---|---|
| Canonical SMILES | CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Cross-Family |
| Avg pChEMBL | 9.22 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB15299 |
|---|---|
| Drug Name | Navtemadlin |
| CAS Number | 1352066-68-2 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Navtemadlin (AMG-232) is under investigation in clinical trial NCT03041688 (MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia). |
Categories: Acids, Acyclic Antineoplastic Agents Fatty Acids Fatty Acids, Volatile Lipids Piperidines
Cross-references: BindingDB: 50448947 CHEMBL3125702 ChemSpider: 31132728 ZINC: ZINC000103248035
Target Activities (2)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| Q00987 | MDM2 | E3 ubiquitin-protein ligase Mdm2 | modulator | targets |